Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: A population-based assessment

Drug and Alcohol Dependence

Volumn 146, Issue 1, 2015, Pages 30-38

  Curtin, Karen ^a   Fleckenstein, Annette E ^b   Robison, Reid J ^c,d   Crookston, Michael J ^c   Smith, Ken R ^a,b   Hanson, Glen R ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c INTERMOUNTAIN HEALTHCARE   (United States)

^d Utah Foundation for Biomedical Research   (United States)

Author keywords

Amphetamine; Cocaine; Dopamine; Drug abuse; Methamphetamine; Parkinson's disease

Indexed keywords

AMPHETAMINE; COCAINE; METHAMPHETAMINE;

ADULT; ARTICLE; COCAINE DEPENDENCE; COHORT ANALYSIS; CONTROLLED STUDY; ESSENTIAL TREMOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHAMPHETAMINE DEPENDENCE; NEUROTOXICITY; PARKINSON DISEASE; PARKINSONISM; POPULATION BASED CASE CONTROL STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; UNITED STATES; AGED; COCAINE-RELATED DISORDERS; COMORBIDITY; DRUG ABUSE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; UTAH;

ADULT; AGED; AMPHETAMINE-RELATED DISORDERS; COCAINE-RELATED DISORDERS; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; UTAH;

EID: 84921024834     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.10.027     Document Type: Article

References (39)

1. Anker J.J., Carroll M.E. Females are more vulnerable to drug abuse than males: evidence from preclinical studies and the role of ovarian hormones. Curr. Top. Behav. Neurosci. 2011, 8:73-96.
2. Bramness J.G., Gundersen O.H., Guterstam J., Rognli E.B., Konstenius M., Loberg E.M., Medhus S., Tanum L., Franck J. Amphetamine-induced psychosis-a separate diagnostic entity or primary psychosis triggered in the vulnerable?. BMC Psychiatry 2012, 12:221.
3. Brecht M.L., O'Brien A., von Mayrhauser C., Anglin M.D. Methamphetamine use behaviors and gender differences. Addict Behav. 2004, 29:89-106.
4. Caligiuri M.P., Buitenhuys C. Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?. Neuropsychopharmacology 2005, 30:2125-2134.
5. Callaghan R.C., Cunningham J.K., Sykes J., Kish S.J. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend. 2011, 120:35-40.
6. Centers for Disease Control and Prevention, 2011. High School Youth Risk Behavior Survey, Utah. Available from 〈http://apps.nccd.cdc.gov/youthonline〉. (accessed 23.01.14.).
7. Curtin K., Smith K.R., Fraser A., Pimentel R., Kohlmann W., Schiffman J.D. Familial risk of childhood cancer and tumors in the Li-Fraumeni spectrum in the Utah Population Database: implications for genetic evaluation in pediatric practice. Int. J. Cancer 2013, 133:2444-2453.
8. Degenhardt L., Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012, 379:55-70.
9. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
10. Fine J., Gray R. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 1999, 94:496-509.
11. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., Hanson G.R. New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 2007, 47:681-698.
12. Garwood E.R., Bekele W., McCulloch C.E., Christine C.W. Amphetamine exposure is elevated in Parkinson's disease. Neurotoxicology 2006, 27:1003-1006.
13. Grant B.F., Hasin D.S., Chou S.P., Stinson F.S., Dawson D.A. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry 2004, 61:1107-1115.
14. Greenfield S.F., Back S.E., Lawson K., Brady K.T. Substance abuse in women. Psychiatr. Clin. North Am. 2010, 33:339-355.
15. Hanson G.R., Rau K.S., Fleckenstein A.E. The methamphetamine experience: a NIDA partnership. Neuropharmacology 2004, 47(Suppl. 1):S92-S100.
16. Kish S.J. Pharmacologic mechanisms of crystal meth. Can. Med. Assoc. J. 2008, 178:1679-1682.
17. Kitamura O. Detection of methamphetamine neurotoxicity in forensic autopsy cases. Leg. Med. (Tokyo) 2009, 11(Suppl. 1):S63-S65.
18. Louis E.D., Applegate L.M., Rios E. ICD-9 CM code 333.1 as an identifier of patients with essential tremor: a study of the positive predictive value of this code. Neuroepidemiology 2007, 28:181-185.
19. National Institutes of Health, 2004. National Institute of Neurological Disorders and Stroke (NINDS). Parkinson's Disease Backgrounder, (accessed 25.01.14). http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease_backgrounder.htm.
20. Noyes K., Liu H., Holloway R., Dick A.W. Accuracy of Medicare claims data in identifying Parkinsonism cases: comparison with the Medicare current beneficiary survey. Mov. Disord. 2007, 22:509-514.
21. Reichel C.M., Chan C.H., Ghee S.M., See R.E. Sex differences in escalation of methamphetamine self-administration: cognitive and motivational consequences in rats. Psychopharmacology (Berl.) 2012, 223:371-380.
22. Roth M.E., Carroll M.E. Sex differences in the acquisition of IV methamphetamine self-administration and subsequent maintenance under a progressive ratio schedule in rats. Psychopharmacology (Berl.) 2004, 172:443-449.
23. Srisurapanont M., Kittiratanapaiboon P., Jarusuraisin N. Treatment for amphetamine psychosis. Cochrane Database Syst. Rev. 2001, 4:CD003026.
24. Substance Abuse and Mental Health Services Administration, 2006. Office of Applied Studies. The National Survey on Drug Use and Health (NSDUH) Report, State Estimates of Past Year Methamphetamine Use. 〈http://www.samhsa.gov/data/2k6/stateMeth/StateMeth.pdf〉 (accessed 01.23.14).
25. Substance Abuse and Mental Health Services Administration, 2011. Office of Applied Studies. Drug Abuse Warning Network, 2008. National Estimates of Drug-Related Emergency Department Visits, Rockville, MD.
26. Substance Abuse and Mental Health Services Administration, 2013. Office of Applied Studies. Results from the 2012 National Survey on Drug Use and Health (NSDUH): Summary of National Findings. HHS Publication no. (SMA) 13-4795.
27. Sung Y.H., Yurgelun-Todd D.A., Shi X.F., Kondo D.G., Lundberg K.J., McGlade E.C., Hellem T.L., Huber R.S., Fiedler K.K., Harrell R.E., Nickerson B.R., Kim S.E., Jeong E.K., Renshaw P.F. Decreased frontal lobe phosphocreatine levels in methamphetamine users. Drug Alcohol Depend. 2013, 129:102-109.
28. Swarztrauber K., Anau J., Peters D. Identifying and distinguishing cases of parkinsonism and Parkinson's disease using ICD-9 CM codes and pharmacy data. Mov. Disord. 2005, 20:964-970.
29. Szumski N.R., Cheng E.M. Optimizing algorithms to identify Parkinson's disease cases within an administrative database. Mov. Disord. 2009, 24:51-56.
30. Tse W., Cersosimo M.G., Gracies J.M., Morgello S., Olanow C.W., Koller W. Movement disorders and AIDS: a review. Parkinsonism Relat. Disord. 2004, 10:323-334.
31. Utah Department of Human Services, 2012. Division of Substance Abuse and Mental Health. Annual Report, 2012. 〈http://www.dsamh.utah.gov/docs/Annual%20report%202012.pdf〉 (accessed 23.01.14).
32. Utah Governor's Office of Planning and Budget, 2012. Census Brief: Race and Ethnicity in Utah (2010). Salt Lake City, Utah.
33. Utah Population Database, 2014. Huntsman Cancer Institute at the University of Utah. Table of Records Available. 〈http://healthcare.utah.edu/huntsmancancerinstitute/research/updb/data/〉 (accessed 25.01.14).
34. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Logan J., Wong C., Miller E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 2001, 158:377-382.
35. Weinberger A.H., Sofuoglu M. The impact of cigarette smoking on stimulant addiction. Am. J. Drug Alcohol Abuse 2009, 35:12-17.
36. White D., Moore S., Waring S., Cook K., Lai E. Identifying incident cases of parkinsonism among veterans using a tertiary medical center. Mov. Disord. 2007, 22:915-923.
37. Willis A.W., Schootman M., Kung N., Racette B.A. Epidemiology and neuropsychiatric manifestations of Young Onset Parkinson's Disease in the United States. Parkinsonism Relat. Disord. 2013, 19:202-206.
38. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996, 2:699-703.
39. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 2011, 26(Suppl. 1):S1-S58.